Zydus Cadila has received tentative USFDA approval to market Brivaracetam Tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (US RLD: Briviact Tablets). 

Brivaracetam tablets are used to treat partial-onset seizures (epilepsy) patients. 

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 319 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. 

Zydus Cadila, an innovative global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and is dedicated to creating healthier communities globally.